Literature DB >> 26488565

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.

D E Neafsey, M Juraska, T Bedford, D Benkeser, C Valim, A Griggs, M Lievens, S Abdulla, S Adjei, T Agbenyega, S T Agnandji, P Aide, S Anderson, D Ansong, J J Aponte, K P Asante, P Bejon, A J Birkett, M Bruls, K M Connolly, U D'Alessandro, C Dobaño, S Gesase, B Greenwood, J Grimsby, H Tinto, M J Hamel, I Hoffman, P Kamthunzi, S Kariuki, P G Kremsner, A Leach, B Lell, N J Lennon, J Lusingu, K Marsh, F Martinson, J T Molel, E L Moss, P Njuguna, C F Ockenhouse, B Ragama Ogutu, W Otieno, L Otieno, K Otieno, S Owusu-Agyei, D J Park, K Pellé, D Robbins, C Russ, E M Ryan, J Sacarlal, B Sogoloff, H Sorgho, M Tanner, T Theander, I Valea, S K Volkman, Q Yu, D Lapierre, B W Birren, P B Gilbert, D F Wirth.   

Abstract

BACKGROUND: The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial protective efficacy against clinical and severe malaria disease in infants and children. We investigated whether the vaccine efficacy was specific to certain parasite genotypes at the circumsporozoite protein locus.
METHODS: We used polymerase chain reaction-based next-generation sequencing of DNA extracted from samples from 4985 participants to survey circumsporozoite protein polymorphisms. We evaluated the effect that polymorphic positions and haplotypic regions within the circumsporozoite protein had on vaccine efficacy against first episodes of clinical malaria within 1 year after vaccination.
RESULTS: In the per-protocol group of 4577 RTS,S/AS01-vaccinated participants and 2335 control-vaccinated participants who were 5 to 17 months of age, the 1-year cumulative vaccine efficacy was 50.3% (95% confidence interval [CI], 34.6 to 62.3) against clinical malaria in which parasites matched the vaccine in the entire circumsporozoite protein C-terminal (139 infections), as compared with 33.4% (95% CI, 29.3 to 37.2) against mismatched malaria (1951 infections) (P=0.04 for differential vaccine efficacy). The vaccine efficacy based on the hazard ratio was 62.7% (95% CI, 51.6 to 71.3) against matched infections versus 54.2% (95% CI, 49.9 to 58.1) against mismatched infections (P=0.06). In the group of infants 6 to 12 weeks of age, there was no evidence of differential allele-specific vaccine efficacy.
CONCLUSIONS: These results suggest that among children 5 to 17 months of age, the RTS,S vaccine has greater activity against malaria parasites with the matched circumsporozoite protein allele than against mismatched malaria. The overall vaccine efficacy in this age category will depend on the proportion of matched alleles in the local parasite population; in this trial, less than 10% of parasites had matched alleles. (Funded by the National Institutes of Health and others.).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26488565      PMCID: PMC4762279          DOI: 10.1056/NEJMoa1505819

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  36 in total

1.  Multiple outputation: inference for complex clustered data by averaging analyses from independent data.

Authors:  Dean Follmann; Michael Proschan; Eric Leifer
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

2.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; Solange Solmeheim Soulanoudjingar; José Francisco Fernandes; Béatrice Peggy Abossolo; Cornelia Conzelmann; Barbara Gaelle Nfono Ondo Methogo; Yannick Doucka; Arnaud Flamen; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Arlindo Nhamuave; Diana Quelhas; Quique Bassat; Sofia Mandjate; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Omar Juma; Mwanajaa Shomari; Kafuruki Shubis; Francisca Machera; Ali Said Hamad; Rose Minja; Ali Mtoro; Alma Sykes; Saumu Ahmed; Alwisa Martin Urassa; Ali Mohammed Ali; Grace Mwangoka; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Marc Christian Tahita; William Kaboré; Sayouba Ouédraogo; Yara Sandrine; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Chris Odero; Martina Oneko; Kephas Otieno; Norbert Awino; Jackton Omoto; John Williamson; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Otsyula Nekoye; Stacey Gondi; Allan Otieno; Bernhards Ogutu; Ruth Wasuna; Victorine Owira; David Jones; Agnes Akoth Onyango; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Jesse Gitaka; Charity Maingi; Trudie Lang; Ally Olotu; Benjamin Tsofa; Philip Bejon; Norbert Peshu; Kevin Marsh; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; Samuel Ayamba; Kingsley Kayan; Ruth Owusu-Ofori; David Dosoo; Isaac Asante; George Adjei; George Adjei; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Hassan Kilavo; Coline Mahende; Edwin Liheluka; Martha Lemnge; Thor Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Alex Agyekum; Larko Owusu; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Ruthendo Nkomo; Albans Msika; Allan Jumbe; Nelecy Chome; Dalitso Nyakuipa; Joseph Chintedza; W Ripley Ballou; Myriam Bruls; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Johan Vekemans; Terrell Carter; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2011-10-18       Impact factor: 91.245

3.  Malaria control, elimination, and eradication: the role of the evolving biomedical research agenda.

Authors:  B Fenton Hall; Anthony S Fauci
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

4.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.

Authors:  Kent E Kester; James F Cummings; Opokua Ofori-Anyinam; Christian F Ockenhouse; Urszula Krzych; Philippe Moris; Robert Schwenk; Robin A Nielsen; Zufan Debebe; Evgeny Pinelis; Laure Juompan; Jack Williams; Megan Dowler; V Ann Stewart; Robert A Wirtz; Marie-Claude Dubois; Marc Lievens; Joe Cohen; W Ripley Ballou; D Gray Heppner
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

5.  Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule.

Authors:  M F Good; D Pombo; I A Quakyi; E M Riley; R A Houghten; A Menon; D W Alling; J A Berzofsky; L H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

6.  Applying Cox regression to competing risks.

Authors:  M Lunn; D McNeil
Journal:  Biometrics       Date:  1995-06       Impact factor: 2.571

7.  Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.

Authors:  P B Gilbert
Journal:  Stat Med       Date:  2000-11-30       Impact factor: 2.373

8.  Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.

Authors:  Ali Alloueche; Paul Milligan; David J Conway; Margaret Pinder; Kalifa Bojang; Tom Doherty; Nadia Tornieporth; Joe Cohen; Brian M Greenwood
Journal:  Am J Trop Med Hyg       Date:  2003-01       Impact factor: 2.345

9.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; José Francisco Fernandes; Béatrice Peggy Abossolo; Barbara Gaelle Nfono Ondo Methogo; Anita Lumeka Kabwende; Ayola Akim Adegnika; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Sonia Machevo; Sozinho Acacio; Helder Bulo; Betuel Sigauque; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Rose Minja; Maxmillian Mpina; Saumu Ahmed; Ali Mohammed Ali; Ali Takadir Mtoro; Ali Said Hamad; Paul Mutani; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Biébo Bihoun; Issa Guiraud; Berenger Kaboré; Olivier Sombié; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Martina Oneko; Chris Odero; Kephas Otieno; Norbert Awino; Meredith McMorrow; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Nekoye Otsyula; Stacey Gondi; Allan Otieno; Victorine Owira; Esther Oguk; George Odongo; Jon Ben Woods; Bernhards Ogutu; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Charity Maingi; Trudie Lang; Ally Olotu; Philip Bejon; Kevin Marsh; Gabriel Mwambingu; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; David Dosoo; Isaac Asante; George Adjei; Evans Kwara; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Coline Mahende; Edwin Liheluka; Lincoln Malle; Martha Lemnge; Thor G Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Anima Sarfo; Alex Agyekum; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Rutendo Nkomo; Tapiwa Tembo; Gerald Tegha; Mercy Tsidya; Jane Kilembe; Chimwemwe Chawinga; W Ripley Ballou; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Aurélie Olivier; Johan Vekemans; Terrell Carter; David Kaslow; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2012-11-09       Impact factor: 91.245

10.  Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.

Authors: 
Journal:  PLoS Med       Date:  2014-07-29       Impact factor: 11.069

View more
  145 in total

1.  Malaria vaccine cautiously recommended for use in Africa.

Authors:  Ewen Callaway; Amy Maxmen
Journal:  Nature       Date:  2015-10-29       Impact factor: 49.962

2.  First proven malaria vaccine rolled out in Africa - but doubts linger.

Authors:  Amy Maxmen
Journal:  Nature       Date:  2019-05       Impact factor: 49.962

Review 3.  Malaria vaccines since 2000: progress, priorities, products.

Authors:  Patrick E Duffy; J Patrick Gorres
Journal:  NPJ Vaccines       Date:  2020-06-09       Impact factor: 7.344

Review 4.  Recent updates in the discovery and development of novel antimalarial drug candidates.

Authors:  John Okombo; Kelly Chibale
Journal:  Medchemcomm       Date:  2018-02-02       Impact factor: 3.597

Review 5.  Phenotypic Screens in Antimalarial Drug Discovery.

Authors:  Marisa L Hovlid; Elizabeth A Winzeler
Journal:  Trends Parasitol       Date:  2016-05-27

6.  The Controlled Human Malaria Infection Experience at the University of Maryland.

Authors:  DeAnna J Friedman-Klabanoff; Matthew B Laurens; Andrea A Berry; Mark A Travassos; Matthew Adams; Kathy A Strauss; Biraj Shrestha; Myron M Levine; Robert Edelman; Kirsten E Lyke
Journal:  Am J Trop Med Hyg       Date:  2019-03       Impact factor: 2.345

7.  Protection against Plasmodium falciparum malaria by PfSPZ Vaccine.

Authors:  Judith E Epstein; Kristopher M Paolino; Thomas L Richie; Martha Sedegah; Alexandra Singer; Adam J Ruben; Sumana Chakravarty; April Stafford; Richard C Ruck; Abraham G Eappen; Tao Li; Peter F Billingsley; Anita Manoj; Joana C Silva; Kara Moser; Robin Nielsen; Donna Tosh; Susan Cicatelli; Harini Ganeshan; Jessica Case; Debbie Padilla; Silas Davidson; Lindsey Garver; Elizabeth Saverino; Tooba Murshedkar; Anusha Gunasekera; Patrick S Twomey; Sharina Reyes; James E Moon; Eric R James; Natasha Kc; Minglin Li; Esteban Abot; Arnel Belmonte; Kevin Hauns; Maria Belmonte; Jun Huang; Carlos Vasquez; Shon Remich; Mary Carrington; Yonas Abebe; Amy Tillman; Bradley Hickey; Jason Regules; Eileen Villasante; B Kim Lee Sim; Stephen L Hoffman
Journal:  JCI Insight       Date:  2017-01-12

Review 8.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

9.  Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Authors:  Joseph R Francica; Daniel E Zak; Caitlyn Linde; Emilio Siena; Carrie Johnson; Michal Juraska; Nicole L Yates; Bronwyn Gunn; Ennio De Gregorio; Barbara J Flynn; Nicholas M Valiante; Padma Malyala; Susan W Barnett; Pampi Sarkar; Manmohan Singh; Siddhartha Jain; Margaret Ackerman; Munir Alam; Guido Ferrari; Andres Salazar; Georgia D Tomaras; Derek T O'Hagan; Alan Aderem; Galit Alter; Robert A Seder
Journal:  Blood Adv       Date:  2017-11-17

10.  Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.

Authors:  Rebecca Kahn; Matt Hitchings; Steven Bellan; Marc Lipsitch
Journal:  Clin Trials       Date:  2018-01-27       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.